Cargando…

Regulatory considerations for generic products of non-biological complex drugs

The Non-Biological Complex Drug (NBCD) Working Group defines an NBCD as “a medicinal product, not being a biological medicine, where the active substance is not a homo-molecular structure, but consists of different (closely related and often nanoparticulate) structures that cannot be isolated and fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yu-Hsuan, Chen, Yi-Shuo, Tseng, Ting, Jiang, Min-Lin, Gau, Churn-Shiouh, Chang, Lin-Chau
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taiwan Food and Drug Administration 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208665/ https://www.ncbi.nlm.nih.gov/pubmed/37224550 http://dx.doi.org/10.38212/2224-6614.3441

Ejemplares similares

The impact of the rare disease and Orphan Drug Act in Taiwan
por: Hsiang, Ning-Chun, et al.
Publicado: (2021)

Patient Involvement in the Health Technology Assessment Process in Taiwan
por: Chen, Kuei An, et al.
Publicado: (2022)

Stem cell therapy on skin: Mechanisms, recent advances and drug reviewing issues
por: Chu, Gong-Yau, et al.
Publicado: (2017)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

Statistical and regulatory considerations in assessments of interchangeability of biological drug products
por: Tóthfalusi, Lászlo, et al.
Publicado: (2014)

Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study
por: Chew, Tan-Wei, et al.
Publicado: (2015)

Valuation of the EQ-5D-5L in Taiwan
por: Lin, Hsiang-Wen, et al.
Publicado: (2018)

Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)

Regulatory considerations for paediatric drug evaluation in China
por: Geng, Ying, et al.
Publicado: (2023)

An expanding horizon of complex injectable products: development and regulatory considerations
por: Panchal, Kanan, et al.
Publicado: (2022)

Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs
por: Hammami, Muhammad M., et al.
Publicado: (2017)

Complex Systems Models in Biology and Medicine: Generic Properties and Applications
por: Serra, Roberto
Publicado: (2014)

Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers
por: Jayachandran, Priya
Publicado: (2023)

A comprehensive study on regulatory requirements for development and filing of generic drugs globally
por: Handoo, Shweta, et al.
Publicado: (2012)

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
por: Eckstein, Niels, et al.
Publicado: (2014)

Generic model for biological regulation
por: Vihinen, Mauno
Publicado: (2022)

Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA)
por: do Carmo, Ana Cerúlia Moraes, et al.
Publicado: (2017)

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
por: Manolis, Efthymios, et al.
Publicado: (2023)

Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs
por: Glerum, Pieter J., et al.
Publicado: (2018)

Policy and Ethical Considerations for Widespread Utilization of Generic Orthopedic Implants
por: Pean, Christian A., et al.
Publicado: (2019)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

The quest for a generic bird target to detect the presence of bird in food products and considerations for paleoprotein analysis
por: Kleinnijenhuis, Anne J., et al.
Publicado: (2022)

Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities
por: Thambavita, D., et al.
Publicado: (2018)

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018)

The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)

Generic drugs – The Indian scenario
por: Joshi, SS, et al.
Publicado: (2019)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

In Silico Methods for Development of Generic Drug–Device Combination Orally Inhaled Drug Products
por: Walenga, Ross L., et al.
Publicado: (2019)

Research and Education Needs for Complex Generics
por: Stern, Sydney, et al.
Publicado: (2021)

Promoting generic drug usage in Japan: correlation between generic drug usage and monthly personal income
por: Suzuki, Takaaki, et al.
Publicado: (2023)

A generic algorithm for layout of biological networks
por: Schreiber, Falk, et al.
Publicado: (2009)

Regulatory filing strategy for generic mesalazine modified release formulations
por: Gupta, Sandeep K.
Publicado: (2011)

Generic antibiotic industries: Challenges and implied strategies with regulatory perspectives
por: Venkatesh, M., et al.
Publicado: (2011)

Requirements for generic anti-epileptic medicines: a regulatory perspective
por: Maliepaard, Marc, et al.
Publicado: (2009)

Effects of hospital generic drug substitution on diabetes therapy
por: Chen, Hui-Yin, et al.
Publicado: (2014)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Determinants of generic drug substitution in Switzerland
por: Decollogny, Anne, et al.
Publicado: (2011)

Issues with generic drugs in Saudi Arabia
por: Asiri, Yousef Abdu, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_fn1s9418p316nig8sbvtvoj6ce